As a seasoned researcher with a keen eye for market trends, I find it fascinating to witness the growing acceptance of Bitcoin by public companies, particularly those in the biotech sector like Anixa Biosciences. This move is not only a testament to the evolving perception of Bitcoin as a mainstream asset class but also a strategic financial decision aimed at bolstering shareholder value.
Biotechnology company, Anixa Biosciences, specializing in cancer research, revealed intentions to bolster its financial approach by investing in Bitcoin, aiming to boost the worth of its shareholders.
In a press release on November 22nd, the biotech company based in San Jose announced their decision to invest a section of their funds into Bitcoin (BTC). They cited the digital currency’s distinctive and resilient properties against inflation as the reason for this move.
In a press release dated November 22nd, Anixa Biosciences announced that their board has given the green light to this move as part of a wider plan to expand their investment portfolio. The company highlighted their robust financial status, boasting a solid cash reserve, which enables them to engage in strategic financial ventures such as investing in Bitcoin, all while continuing to progress clinical trials and ensuring shareholder profits.
Given the rising acceptance of Bitcoin as a conventional investment option, we think incorporating it into our reserves makes strategic sense. The green light given to Bitcoin ETFs and growing involvement of institutional investors underscores its significance in international financial markets.
Mike Catelani, president and CFO of Anixa
Amit Kumar, CEO of Anixa, emphasized their methodical strategy for handling finances. He explained that investing in Bitcoin is an extra measure to wise financial management, contributing significantly to increased shareholder worth. This revelation led to a surge of 7.84% in Anixa’s shares during pre-market trading.
Public companies rush to embrace Bitcoin as treasury asset
The move aligns with a growing trend among public companies incorporating Bitcoin into their financial strategies. Artificial intelligence firm Genius Group recently also announced $4 million in BTC purchases, raising its holdings to 153 BTC as part of its “Bitcoin-first” strategy to allocate 90% or more of its reserves to the cryptocurrency.
Alongside firms like MicroStrategy and Acurx, listed on Nasdaq, have increased their investments in Bitcoin. They see it as a valuable asset for safeguarding against inflation and a technology-backed store of worth that’s worth capitalizing on.
Read More
- XRP Price Eyes $2 Support Level Amidst Market Correction
- 15 Charged for converting Drug Cartels’ Cash into Cryptocurrency in U.S.
- OREO Unveils Six New Products for 2025
- PYTH PREDICTION. PYTH cryptocurrency
- ‘Fast and Furious’ Star Paul Walker Remembered 11 Years After His Death
- Russell T Davies Says He “Kind Of Hopes” The Streaming Bubble Will “Pop”
- Apple Lands Anya Taylor-Joy Led Drama ‘Lucky,’ Based on Bestseller
- Paul Atkins to Replace Gary Gensler as Next SEC Chair?
- Crypto VC funding roundup: Riot snags over $594m, BVNK raises $50m
- Google’s Willow Quantum Chip Sparks Bitcoin Security Debate
2024-11-22 17:07